Cortical Thin Patch Fraction Reflects Disease Burden in MS: The Mosaic Approach

References

1. 1.↵
   2. Lassmann H

   . Multiple sclerosis pathology. Cold Spring Harb Perspect Med 2018;8:a028936 doi:10.1101/cshperspect.a028936 pmid:29358320

   Abstract/FREE Full Text
2. 2.↵
   2. Friese MA,
   3. Schattling B,
   4. Fugger L

   . Mechanisms of neurodegeneration and axonal dysfunction in multiple sclerosis. Nat Rev Neurol 2014;10:225–38 doi:10.1038/nrneurol.2014.37 pmid:24638138

   CrossRefPubMed
3. 3.↵
   2. Thompson AJ,
   3. Banwell BL,
   4. Barkhof F, et al

   . Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol 2018;17:162–73 doi:10.1016/S1474-4422(17)30470-2 pmid:29275977

   CrossRefPubMed
4. 4.↵
   2. Klineova S,
   3. Lublin FD

   . Clinical course of multiple sclerosis. Cold Spring Harb Perspect Med 2018;8:a028928 doi:10.1101/cshperspect.a028928 pmid:29358317

   Abstract/FREE Full Text
5. 5.↵
   2. Lublin FD

   . New multiple sclerosis phenotypic classification. Eur Neurol 2014;72(Suppl 1):1–5 doi:10.1159/000367614 pmid:25278115

   CrossRefPubMed
6. 6.↵
   2. Rotstein D,
   3. Montalban X

   . Reaching an evidence-based prognosis for personalized treatment of multiple sclerosis. Nat Rev Neurol 2019;15:287–300 doi:10.1038/s41582-019-0170-8 pmid:30940920

   CrossRefPubMed
7. 7.↵
   2. Todea RA,
   3. Lu PJ,
   4. Fartaria MJ, et al

   . Evolution of cortical and white matter lesion load in early-stage multiple sclerosis: correlation with neuroaxonal damage and clinical changes. Front Neurol 2020;11:973 doi:10.3389/fneur.2020.00973 pmid:33013644

   CrossRefPubMed
8. 8.↵
   2. Engl C,
   3. Tiemann L,
   4. Grahl S, et al

   . Cognitive impairment in early MS: contribution of white matter lesions, deep grey matter atrophy, and cortical atrophy. J Neurol 2020;267:2307–18 doi:10.1007/s00415-020-09841-0 pmid:32328718

   CrossRefPubMed
9. 9.↵
   2. Mollison D,
   3. Sellar R,
   4. Bastin M, et al

   . The clinico-radiological paradox of cognitive function and MRI burden of white matter lesions in people with multiple sclerosis: a systematic review and meta-analysis. PLoS One 2017;12:e0177727–16 doi:10.1371/journal.pone.0177727 pmid:28505177

   CrossRefPubMed
10. 10.↵
    2. Cortese R,
    3. Collorone S,
    4. Ciccarelli O, et al

    . Advances in brain imaging in multiple sclerosis. Ther Adv Neurol Disord 2019;12:1756286419859722 doi:10.1177/1756286419859722 pmid:31275430

    CrossRefPubMed
11. 11.↵
    2. Uher T,
    3. Vaneckova M,
    4. Krasensky J, et al

    . Pathological cut-offs of global and regional brain volume loss in multiple sclerosis. Mult Scler 2019;25:541–53 doi:10.1177/1352458517742739 pmid:29143562

    CrossRefPubMed
12. 12.↵
    2. De Stefano N,
    3. Giorgio A,
    4. Battaglini M, et al

    . Assessing brain atrophy rates in a large population of untreated multiple sclerosis subtypes. Neurology 2010;74:1868–76 doi:10.1212/WNL.0b013e3181e24136 pmid:20530323

    Abstract/FREE Full Text
13. 13.↵
    2. Eshaghi A,
    3. Prados F,
    4. Brownlee WJ, et al

    ; MAGNIMS Study Group. Deep gray matter volume loss drives disability worsening in multiple sclerosis. Ann Neurol 2018;83:210–22 doi:10.1002/ana.25145 pmid:29331092

    CrossRefPubMed
14. 14.↵
    2. Wattjes MP,
    3. Ciccarelli O,
    4. Reich DS, et al

    ; North American Imaging in Multiple Sclerosis Cooperative MRI guidelines working group. 2021 MAGNIMS–CMSC–NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis. Lancet Neurol 2021;20:653–70 doi:10.1016/S1474-4422(21)00095-8 pmid:34139157

    CrossRefPubMed
15. 15.↵
    2. Amiri H,
    3. de Sitter A,
    4. Bendfeldt K, et al

    ; MAGNIMS Study Group. Urgent challenges in quantification and interpretation of brain grey matter atrophy in individual patients with MS using MRI. Neuroimage Clin 2018;19:466–75 doi:10.1016/j.nicl.2018.04.023 pmid:29984155

    CrossRefPubMed
16. 16.↵
    2. Shafto M,
    3. Tyler LK,
    4. Dixon M, et al

    ; Cam-CAN. The Cambridge Centre for Ageing and Neuroscience (Cam-CAN) study protocol: a cross-sectional, lifespan, multidisciplinary examination of healthy cognitive ageing. BMC Neurol 2014;14:204 doi:10.1186/s12883-014-0204-1 pmid:25412575

    CrossRefPubMed
17. 17.↵
    2. Van Essen DC,
    3. Smith SM,
    4. Barch DM, et al

    ; WU-Minn HCP Consortium. The WU-Minn Human Connectome Project: an overview. Neuroimage 2013;80:62–79 doi:10.1016/j.neuroimage.2013.05.041 pmid:23684880

    CrossRefPubMedWeb of Science
18. 18.↵
    2. Alfaro-Almagro F,
    3. Jenkinson M,
    4. Bangerter NK, et al

    . Image processing and quality control for the first 10,000 brain imaging datasets from UK Biobank. Neuroimage 2018;166:400–24 doi:10.1016/j.neuroimage.2017.10.034 pmid:29079522

    CrossRefPubMed
19. 19.↵
    2. Tahedl M

    . Towards individualized cortical thickness assessment for clinical routine. J Transl Med 2020;18:151 doi:10.1186/s12967-020-02317-9 pmid:32245485

    CrossRefPubMed
20. 20.↵
    2. Tahedl M,
    3. Chipika RH,
    4. Lope J, et al

    . Cortical progression patterns in individual ALS patients across multiple timepoints: a mosaic-based approach for clinical use. J Neurol 2021;268:1913–26 doi:10.1007/s00415-020-10368-7 pmid:33399966

    CrossRefPubMed
21. 21.↵
    2. Tahedl M,
    3. Shing SL,
    4. Finegan E, et al

    . Propagation patterns in motor neuron diseases: Individual and phenotype-associated disease-burden trajectories across the UMN-LMN spectrum of MNDs. Neurobiol Aging 2022;109:78–87 doi:10.1016/j.neurobiolaging.2021.04.031 pmid:34656922

    CrossRefPubMed
22. 22.↵
    2. McKenna MC,
    3. Tahedl M,
    4. Lope J, et al

    . Mapping cortical disease-burden at individual-level in frontotemporal dementia: implications for clinical care and pharmacological trials. Brain Imaging Behav 2022;16:1196–207 doi:10.1007/s11682-021-00523-7 pmid:34882275

    CrossRefPubMed
23. 23.↵
    2. Schmidt P,
    3. Gaser C,
    4. Arsic M, et al

    . An automated tool for detection of FLAIR-hyperintense white-matter lesions in multiple sclerosis. Neuroimage 2012;59:3774–83 doi:10.1016/j.neuroimage.2011.11.032 pmid:22119648

    CrossRefPubMed
24. 24.↵
    2. Yaldizli Ö,
    3. Penner IK,
    4. Frontzek K, et al

    . The relationship between total and regional corpus callosum atrophy, cognitive impairment and fatigue in multiple sclerosis patients. Mult Scler 2014;20:356–64 doi:10.1177/1352458513496880 pmid:23959709

    CrossRefPubMed
25. 25.↵
    2. Calabrese P,
    3. Kalbe E,
    4. Kessler J

    . Ein neuropsychologisches Screening zur Erfassung kognitiver Störungen bei MS-Patienten: Das Multiple Sklerose Inventarium Cognition (MUSIC). Psychoneuro 2004;30:384–88 doi:10.1055/s-2004-831083

    CrossRef
26. 26.↵
    2. Fischl B

    . FreeSurfer. Neuroimage 2012;62:774–81 doi:10.1016/j.neuroimage.2012.01.021 pmid:22248573

    CrossRefPubMedWeb of Science
27. 27.↵
    2. Dale AM,
    3. Fischl B,
    4. Sereno MI

    . Cortical surface-based analysis, I: segmentation and surface reconstruction. Neuroimage 1999;9:179–94 doi:10.1006/nimg.1998.0395 pmid:9931268

    CrossRefPubMedWeb of Science
28. 28.↵
    2. Fischl B,
    3. Sereno MI,
    4. Dale AM

    . Cortical surface-based analysis. II: Inflation, flattening, and a surface-based coordinate system. Neuroimage 1999;9:195–207 doi:10.1006/nimg.1998.0396 pmid:9931269

    CrossRefPubMedWeb of Science
29. 29.↵
    2. Dickie EW,
    3. Anticevic A,
    4. Smith DE, et al

    . Ciftify: a framework for surface-based analysis of legacy MR acquisitions. Neuroimage 2019;197:818–26 doi:10.1016/j.neuroimage.2019.04.078 pmid:31091476

    CrossRefPubMed
30. 30.↵
    2. Schaefer A,
    3. Kong R,
    4. Gordon EM, et al

    . Local-global parcellation of the human cerebral cortex from intrinsic functional connectivity MRI. Cereb Cortex 2018;28:3095–114 doi:10.1093/cercor/bhx179 pmid:28981612

    CrossRefPubMed
31. 31.↵
    2. Nichols TE,
    3. Holmes AP

    . Nonparametric permutation tests for functional neuroimaging: A primer with examples. Hum Brain Mapp 2002;15:1–25 doi:10.1002/hbm.1058 pmid:11747097

    CrossRefPubMedWeb of Science
32. 32.↵
    2. Diedenhofen B,
    3. Musch J

    . cocor: a comprehensive solution for the statistical comparison of correlations. PLoS One 2015;10:e0121945 doi:10.1371/journal.pone.0121945 pmid:25835001

    CrossRefPubMed
33. 33.↵
    2. Hittner JB,
    3. May K,
    4. Silver NC

    . A Monte Carlo evaluation of tests for comparing dependent correlations. J Gen Psychol 2003;130:149–68 doi:10.1080/00221300309601282 pmid:12773018

    CrossRefPubMedWeb of Science
34. 34.↵
    2. Durand-Dubief F,
    3. Belaroussi B,
    4. Armspach JP, et al

    . Reliability of longitudinal brain volume loss measurements between 2 sites in patients with multiple sclerosis: comparison of 7 quantification techniques. AJNR Am J Neuroradiol 2012;33:1918–24 doi:10.3174/ajnr.A3107 pmid:22790248

    Abstract/FREE Full Text
35. 35.↵
    2. Biberacher V,
    3. Schmidt P,
    4. Keshavan A, et al

    . Intra- and interscanner variability of magnetic resonance imaging based volumetry in multiple sclerosis. Neuroimage 2016;142:188–97 doi:10.1016/j.neuroimage.2016.07.035 pmid:27431758

    CrossRefPubMed
36. 36.↵
    2. Bethlehem RA,
    3. Seidlitz J,
    4. White SR, et al

    ; VETSA. Brain charts for the human lifespan. Nature 2022;604:525–33 doi:10.1038/s41586-022-04554-y pmid:35388223

    CrossRefPubMed
37. 37.↵
    2. Tsagkas C,
    3. Parmar K,
    4. Pezold S, et al

    . Classification of multiple sclerosis based on patterns of regional atrophy covariance. Hum Brain Mapp 2021;42:2399–415 doi:10.1002/hbm.25375 pmid:33624390

    CrossRefPubMed
38. 38.↵
    2. Tsagkas C,
    3. Chakravarty MM,
    4. Gaetano L, et al

    . Longitudinal patterns of cortical thinning in multiple sclerosis. Hum Brain Mapp 2020;41:2198–215 doi:10.1002/hbm.24940 pmid:32067281

    CrossRefPubMed
39. 39.↵
    2. Steenwijk MD,
    3. Geurts JJ,
    4. Daams M, et al

    . Cortical atrophy patterns in multiple sclerosis are non-random and clinically relevant. Brain 2016;139:115–26 doi:10.1093/brain/awv337 pmid:26637488

    CrossRefPubMed
40. 40.↵
    2. Rocca MA,
    3. Valsasina P,
    4. Meani A, et al

    ; MAGNIMS Study Group. Association of gray matter atrophy patterns with clinical phenotype and progression in multiple sclerosis. Neurology 2021;96:e1561–73 doi:10.1212/WNL.0000000000011494 pmid:33441452

    Abstract/FREE Full Text
41. 41.↵
    2. Eijlers AJ,
    3. Dekker I,
    4. Steenwijk MD, et al

    . Cortical atrophy accelerates as cognitive decline worsens in multiple sclerosis. Neurology 2019;93:e1348–59 doi:10.1212/WNL.0000000000008198 pmid:31484713

    Abstract/FREE Full Text
42. 42.↵
    2. Munster CV,
    3. Uitdehaag BM

    . Outcome measures in clinical trials for multiple sclerosis. CNS Drugs 2017;31:217–36 doi:10.1007/s40263-017-0412-5 pmid:28185158

    CrossRefPubMed
43. 43.↵
    2. Vaughn CB,
    3. Jakimovski D,
    4. Kavak KS, et al

    . Epidemiology and treatment of multiple sclerosis in elderly populations. Nat Rev Neurol 2019;15:329–42 doi:10.1038/s41582-019-0183-3 pmid:31000816

    CrossRefPubMed
44. 44.↵
    2. Sorensen PS,
    3. Sellebjerg F,
    4. Hartung HP, et al

    . The apparently milder course of multiple sclerosis: changes in the diagnostic criteria, therapy and natural history. Brain 2020;143:2637–52 doi:10.1093/brain/awaa145 pmid:32710096

    CrossRefPubMed
45. 45.↵
    2. Pourhoseingholi MA,
    3. Baghestani AR,
    4. Vahedi M

    . How to control confounding effects by statistical analysis. Gastroenterol Hepatol Bed Bench 2012;5:79–83 pmid:24834204

    PubMed
46. 46.↵
    2. Charil A,
    3. Dagher A,
    4. Lerch JP, et al

    . Focal cortical atrophy in multiple sclerosis: relation to lesion load and disability. Neuroimage 2007;34:509–17 doi:10.1016/j.neuroimage.2006.10.006 pmid:17112743

    CrossRefPubMedWeb of Science
47. 47.↵
    2. Schoonheim MM,
    3. Pinter D,
    4. Prouskas SE, et al

    . Disability in multiple sclerosis is related to thalamic connectivity and cortical network atrophy. Mult Scler 2022;28:61–70 doi:10.1177/13524585211008743 pmid:33870779

    CrossRefPubMed
48. 48.↵
    2. Dillenseger A,
    3. Weidemann ML,
    4. Trentzsch K, et al

    . Digital biomarkers in multiple sclerosis. Brain Sci 2021;11:1519 doi:10.3390/brainsci11111519 pmid:34827518

    CrossRefPubMed
49. 49.↵
    2. Yang J,
    3. Hamade M,
    4. Wu Q, et al

    . Current and future biomarkers in multiple sclerosis. Int J Mol Sci 2022;23:5877 doi:10.3390/ijms23115877 pmid:35682558

    CrossRefPubMed
50. 50.↵
    2. Filippi M,
    3. Agosta F

    . Imaging biomarkers in multiple sclerosis. J Magn Reson Imaging 2010;31:770–88 doi:10.1002/jmri.22102 pmid:20373420

    CrossRefPubMed